AUTHORS
Adriana Rossi, MD, Binod Dhakal, MD, MS2, David S Siegel, MD, PhD3, Daniel W. Sherbenou, MD, PhD4, Faiz Anwer, MD5, Doug W. Sborov, MD, MS6, Manisha Bhutani, MD7, William Clark, MD8, James Essell, MD9, Ahmed Galal10, Larry D Anderson Jr, MD, PhD11, Chris Holland, MS12, Pingping Mao, PhD13, Eric Stawiski, PhD14, Ash Garrett, PharmD15, Kike Zudaire, PhD16, Wellington Mendes, MD17, Socorro Portella, MD, MBA18, Sundar Jagannath, M.D.19, Luciano J. Costa, MD, PhD20
AFFILIATIONS
1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, United States
6 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
8 VCU Massey Cancer Center, Richmond, Virginia, United States
9 Cincinnati Cancer Advisors, Cincinnati, Ohio, United States
10 US Oncology, OHC, The Jewish Hospital, Cincinnati, Ohio, United States
11 UT Southwestern Medical Center, Dallas, Texas, United States
12 Caribou Biosciences, Inc., Berkeley, California, United States
13 Caribou Biosciences, Inc., Berkeley, California, United States
14 Caribou Biosciences, Inc., Berkeley, California, United States
15 Caribou Biosciences, Inc., Berkeley, California, United States
16 Caribou Biosciences, Inc., Berkeley, California, United States
17 Caribou Biosciences, Inc., Berkeley, California, United States
18 Caribou Biosciences, Inc., Berkeley, California, United States
19 Icahn School of Medicine at Mount Sinai, New York, New York, United States
20 The University of Alabama, Birmingham, Alabama, United States
ABSTRACT
Background: CB-011 is an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking manufactured from healthy donor T cells. It features 4 genome edits made with the CRISPR-Cas12a chRDNA genome-editing technology: (1) insertion of a BCMA-specific CAR, (2) TRAC gene knockout (KO) to reduce risk of graft-versus-host disease (GvHD), (3) KO of B2M to reduce T cell-mediated rejection, and (4) B2M–HLA-E fusion insertion to blunt natural killer (NK) cell-mediated rejection.
Aims: CaMMouflage is a Phase 1 trial (NCT05722418) comprised of a 3+3 dose escalation and dose expansion portion to evaluate the safety and efficacy of CB-011 in patients (pts) with r/r MM.
Methods: Pts received ≥3 prior lines of therapy (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody). Lymphodepletion (LD) was administered for 3 days of either 300 cyclophosphamide (cy) or 500 cy (300 mg/m2 or 500 mg/m2 of cy, respectively) with 30 mg/m2 of fludarabine followed by a single infusion of CB-011 at dose levels of 50 million (M), 150M, 300M, 450M, or 800M CAR-T cells.
Results: As of April 20, 2026, a total of 48 pts received CB-011 in dose escalation. The median age was 68.5 years (49-84). Pts received a median of 4 prior lines of therapy (3-11), and 17% received prior BCMA-targeted therapy. 56% of pts had high-risk cytogenetics and 33% had extramedullary disease. Of the 13 pts dosed in the 300 cy LD cohort, only one pt experienced CAR-T cell expansion. That pt achieved a minimal residual disease (MRD)-negative stringent complete response (sCR) still ongoing at 24 months post CB-011; therefore, the 500 cy LD regimen was implemented to optimize CAR-T cell expansion. In pts who received the 500 cy LD regimen (N=35), infections occurred in 49% of pts (17%, grade ≥3), cytokine release syndrome (CRS) occurred in 34% of pts (3%, grade ≥3), immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 9% of pts (no grade ≥3), IEC-HS occurred in 9% of pts (3%, grade ≥3), and prolonged grade ≥3 cytopenias occurred in 35% of pts. No cases of GvHD, immune effector cell-associated enterocolitis, parkinsonism, or cranial nerve palsies were observed at any dose level. One grade 4 event of Guillain-Barré syndrome (GBS) occurred at day 129 and is resolving. Three grade 5 AEs occurred at the 450M dose level (ICAHT on day 90 [related], pneumonia on day 50 [unrelated], respiratory acidosis on day 466 [unrelated]), and one grade 5 AE occurred at the 300M dose level (respiratory syncytial virus on day 73 [unrelated]). Following these events, additional prophylactic measures and earlier intervention have been implemented. For BCMA-naïve pts who received the recommended dose for expansion (RDE; 500 cy LD and 450M CAR-T cell dose) of CB-011 (N=12), the ORR was 92% and the ≥ CR rate was 83%. Of the MRD-evaluable pts, 10/11 (91%) achieved MRD negativity at the 10-5 threshold. CB-011 exhibited a central memory CD8 T cell phenotype at peak of expansion. CB-011 expansion directly correlated with clinical responses and was higher in pts treated with 500 cy compared with 300 cy LD. Rapid recovery of endogenous T and NK cells was observed and endogenous B cells recovered within 6 months regardless of clinical response. Updated clinical and translational data will be presented, including initial dose expansion data from prior BCMA-exposed r/r MM patients.
Summary/Conclusions: In a high-risk, heavily pretreated r/r MM pt population, CB-011 demonstrated deep and durable responses with a manageable safety profile. Enrollment of BCMA-naïve and prior BCMA-exposed r/r MM patients is ongoing in the dose expansion portion of the CaMMouflage trial.
DISCLOSURES
Adriana Rossi, MD: Caribou Biosciences, Inc. - Honoraria; Sanofi - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Caribou Biosciences, Inc. - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)